LAK1 Antigen and Tumor Infiltrating Lymphocytes
Author Information
Author(s): M. Ferrarini, E. Ferrero, C. Fortis, A. Poggi, M. Raffaella Zocchi
Primary Institution: Istituto Scientifico San Raffaele
Hypothesis
Can LAK1 antigen distinguish between two populations of tumor infiltrating lymphocytes with specific or non-MHC-restricted activity?
Conclusion
The study concludes that LAK1 antigen can differentiate tumor infiltrating lymphocytes into two subsets with distinct functional properties.
Supporting Evidence
- About 25% of tumor infiltrating lymphocytes were weakly stained with anti-LAK1 monoclonal antibody.
- After culture in interleukin-2, the percentage of LAK1+ cells increased to 50%.
- Specific lytic activity was mainly evident in LAK1- lymphocytes.
Takeaway
Researchers found that a specific marker, LAK1, helps tell apart two types of immune cells that fight tumors, showing that some cells are better at targeting tumors than others.
Methodology
The study involved culturing tumor infiltrating lymphocytes from lung and renal tumors in the presence of interleukin-2 and analyzing their phenotype and function.
Limitations
The study does not clarify the exact role of these lymphocyte subsets in tumor control.
Participant Demographics
Participants included patients with primary lung tumors and renal cell carcinomas.
Want to read the original?
Access the complete publication on the publisher's website